ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
Dow Jones
44.544,66
-0,75%
Euro vs US Dollar
1,03615
0,00%
Bitcoin
102.154,97
-0,25%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Autolus Therapeutics PLC (AUTL)

  7. Autolus Therapeutics PLC (AUTL) News

AUTL

Autolus Therapeutics (AUTL)

Autolus Therapeutics PLC
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AUTL
DatumZeitQuelleÜberschriftSymbolFirma
17/01/202513h00GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem MeetingsNASDAQ:AUTLAutolus Therapeutics PLC
13/01/202513h00GlobeNewswire Inc.Autolus Therapeutics Provides Business Updates and 2025 OverviewNASDAQ:AUTLAutolus Therapeutics PLC
10/12/202401h30GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024NASDAQ:AUTLAutolus Therapeutics PLC
02/12/202413h00GlobeNewswire Inc.Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of MedicineNASDAQ:AUTLAutolus Therapeutics PLC
14/11/202422h32Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
14/11/202422h09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AUTLAutolus Therapeutics PLC
14/11/202415h12Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
12/11/202422h27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AUTLAutolus Therapeutics PLC
12/11/202413h54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
12/11/202413h00GlobeNewswire Inc.Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
12/11/202412h56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
08/11/202422h23GlobeNewswire Inc.Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)NASDAQ:AUTLAutolus Therapeutics PLC
05/11/202415h00GlobeNewswire Inc.Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster PresentationsNASDAQ:AUTLAutolus Therapeutics PLC
28/10/202422h00GlobeNewswire Inc.Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024NASDAQ:AUTLAutolus Therapeutics PLC
25/10/202422h01Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
16/10/202415h00GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma CongressNASDAQ:AUTLAutolus Therapeutics PLC
26/09/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
19/09/202414h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
19/09/202413h00GlobeNewswire Inc.Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development OfficerNASDAQ:AUTLAutolus Therapeutics PLC
16/09/202423h02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AUTLAutolus Therapeutics PLC
13/09/202415h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
27/08/202413h00GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024NASDAQ:AUTLAutolus Therapeutics PLC
08/08/202422h21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AUTLAutolus Therapeutics PLC
08/08/202414h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
08/08/202413h00GlobeNewswire Inc.Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
26/07/202413h00GlobeNewswire Inc.Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024NASDAQ:AUTLAutolus Therapeutics PLC
14/06/202413h00GlobeNewswire Inc.Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressNASDAQ:AUTLAutolus Therapeutics PLC
05/06/202422h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
03/06/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
31/05/202414h00GlobeNewswire Inc.Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCONASDAQ:AUTLAutolus Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AUTL

Kürzlich von Ihnen besucht

NYSE
DIS
Walt Disney
NYSE
JPM
JP Morgan Chase
TG
TUI1
Tui
NYSE
NKE
Nike
NYSE
MCD
McDonalds
USOTC
DTEGY
Deutsche Telekom (QX)
TG
BAYN
Bayer
AMEX
SPY
SPDR S&P 500
COIN
DOGEUSD
Dogecoin
TG
MBG
MercedesBenz
FX
EURUSD
Euro vs US Dollar
TG
DTE
Deutsche Telekom
TG
LHA
Deutsche Lufthansa
NASDAQ
TSLA
Tesla
COIN
ADAUSD
Cardano
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten